Keywords: Arrowhead Research, RNAi, Solid tumors, Obesity, Hepatitits B, Adipotide, Edison Investment Research

Arrowhead Research Corp improving focus, say Edison analysts

Article | 16 August 2012

Print This

Last year’s acquisition of Roche’s RNAi (RNA interference) business (The Pharma Letter October 25, 2011) makes USA-based nano-medicine ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in